ACAM2000

ACAM2000

A live smallpox vaccine manufactured from vaccinia cell cultures (a related orthopoxvirus).
References in periodicals archive ?
ACAM2000 is the only FDA-licensed vaccine for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection.
Once the deal completes, Emergent will acquire ACAM2000 (smallpox (vaccinia) vaccine, live), which is claimed to be the only vaccine approved by the US Food and Drug Administration for active immunisation against smallpox disease for patients with high risk of infection.
On February 4, 2016, the New Mexico Department of Health (NMDOH) was contacted regarding a patient who had received ACAM2000 * smallpox (vaccinia) vaccine 12 days earlier as part of an institutional review board-approved study at a plasma donation center and had numerous lesions surrounding the inoculation site and on the opposite arm, back, and abdomen.
In June 2015, ACIP, having reviewed recent clinical data, reaffirmed the CDC's standing recommendations that the live vaccinia virus smallpox vaccine ACAM2000 (which replaced Dryvax in 2008) be administered routinely to those with occupational exposure to orthopox viruses (eg, laboratory personnel who work with monkeypox, variola, or smallpox viruses).
Currently unlicensed third-generation smallpox vaccines may be considered (pending licensure) as replacements to ACAM2000 (Sanofi Pasteur Biologics, Lyon, France), the currently licensed vaccinia vaccine, for laboratory workers at national variola testing sites or perhaps an even broader population of laboratory workers throughout the United States.
Another example is also the Acambis ACAM2000 smallpox vaccine which is made in a Vero cell line using disposable production technology.
Vaccinia virus was confirmed in all four patients, and gene sequencing in three of the cases linked the virus to the ACAM2000 smallpox vaccine.
The Food and Drug Administration has approved a new smallpox vaccine, ACAM2000, for active immunization against smallpox in individuals determined to be at high risk for smallpox infection.
In May, the Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee voted 11-0 in favor of both the safety and efficacy of the vaccine, marketed as ACAM2000.
The panel agreed unanimously that the vaccine, ACAM2000, would protect people considered at high risk of exposure in a smallpox outbreak.
Shares in Acambis, who are best known for developing the smallpox vaccine ACAM2000, rose three per cent yesterday
Acambis is best known for vaccines such as ACAM2000, which inoculates peopleagainst smallpox and has been stockpiled by the US Government